top of page
  • Recruiting

NCT02833610: Phase 2 - A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Updated: Apr 26, 2022


NCT02833610: Phase 2 - A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency


denosumab

This research study is studying a possible therapy as a possible treatment for the consequences of Multiple Myeloma with renal insufficiency.


Sponsor:

Massachusetts General Hospital


Collaborators:

Amgen

Emory University

University of Rochester

University Hospitals Cleveland Medical Center


Multiple locations


ClinicalTrials.gov Identifier: NCT02833610

Official Title: A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

https://clinicaltrials.gov/ct2/show/NCT02833610

 

Denosumab: National Cancer Institute

Denosumab: MedlinePlus Drug Information

 

Drug: Denosumab Q4W





Posts Archive
bottom of page